Clinical Trial Update: Analysis of the Real-world Prescription Pattern of Palbociclib Combination Therapy With Aromatase Inhibitor as a First Line Therapy in Metastatic Breast Cancer Patients Using the National Health Insurance Claims Data in South Korea

View source ↗

Summary

A completed real-world study analyzing palbociclib in combination with aromatase inhibitors as first-line therapy for metastatic breast cancer using South Korea…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• ARIMIDEX (anastrozole)
• FEMARA (letrozole)
• IBRANCE (PALBOCICLIB)

Snippet

Sponsor: Pfizer | Conditions: Metastatic Breast Cancer | Status: COMPLETED